Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: Results from a safety lead-in study

International Journal of Gynecological Cancer

Volumn 19, Issue 9, 2009, Pages 1504-

  Vergote, Ignace ^a   Amant, Frederic ^a   Oskay Öezcelik, Gülten ^b   Musib, Luna ^c   Michel, Anne Laure ^d   Darstein, Christelle ^c   Kania, Marek ^c   Bauknecht, Thomas ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c ELI LILLY AND COMPANY   (United States)

^d Bad Homburg vor der Höhe ^*  (France)

^e LILLY DEUTSCHLAND GMBH   (Germany)

Author keywords

Advanced ovarian cancer; Carboplatin; Enzastaurin; Paclitaxel; Safety

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; ENZASTAURIN; INDOLE DERIVATIVE; PACLITAXEL;

ADJUVANT THERAPY; ADULT; AGED; ALGORITHM; ARTICLE; CARCINOMA; CLINICAL TRIAL; DISEASE COURSE; DRUG INTERACTION; FEMALE; HUMAN; METABOLISM; METASTASIS; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; OVARY TUMOR; PATHOLOGY; PERITONEUM TUMOR;

ADMINISTRATION, ORAL; ADULT; AGED; ALGORITHMS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA; DISEASE PROGRESSION; DRUG INTERACTIONS; FEMALE; HUMANS; INDOLES; MIDDLE AGED; NEOADJUVANT THERAPY; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS;

EID: 85026149526     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181bda1a7     Document Type: Article

References (0)